Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs

INTRODUCTION: Assess the cost-effectiveness (US healthcare payer perspective) of sarilumab subcutaneous (SC) 200 mg + methotrexate versus conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or targeted DMARD + methotrexate for moderate-to-severe rheumatoid arthritis (RA) in adul...

Descripción completa

Detalles Bibliográficos
Autores principales: Muszbek, Noemi, Proudfoot, Clare, Fournier, Marie, Chen, Chieh-I, Kuznik, Andreas, Kiss, Zsofia, Gal, Peter, Michaud, Kaleb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824456/
https://www.ncbi.nlm.nih.gov/pubmed/31004324
http://dx.doi.org/10.1007/s12325-019-00946-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824456/
https://www.ncbi.nlm.nih.gov/pubmed/31004324
http://dx.doi.org/10.1007/s12325-019-00946-1

Ejemplares similares